Nanobiotix Stock Surges +807% Over the Year and Continues Its Rise This Wednesday

Strong Long-Term Uptrend

The Nanobiotix stock is currently well above its 50-day moving average (€24.05) and significantly above the 200-day average (€15.84), indicating a firmly established upward trend in both the medium and long term. The gap of more than 8 points between the MM50 and MM200 confirms the magnitude of the movement observed in recent months, with an appreciation of 47% in just the last three months alone. The RSI, at 48, is in a neutral zone, far from overbought or oversold thresholds, suggesting that the stock still has room to fluctuate in both directions. The current price (€26.76) is positioned in the lower part of the Bollinger Bands, at 38% between the lower bound (€23.41) and the upper bound (€32.24). The identified resistance threshold is at €33.50, a level still distant from the current price. Monthly volatility remains high, at 23.46%, characteristic of a growth stock with low capitalization.

Outperforming Sector Peers

Nanobiotix's twelve-month performance exceeds 807%, a trajectory that stands out compared to the more measured path of other health sector players listed in Europe. For comparison, Sanofi shows a session change of +0.37% this Wednesday, while UCB is up 0.95%. The beta of 0.22 indicates a very low correlation with general market movements, meaning that the stock's performance is more responsive to company-specific catalysts than to macroeconomic trends. Over the last week, the gain reached 3.52%, confirming the continuation of an upward movement after a consolidation phase. The stock had closed at €25.62 the previous day, and this morning's rebound brings it closer to its 20-day moving average (€27.82), a level that could serve as a short-term observation point for stakeholders.